Currently, nutraceuticals and functional food/cosmeceutical sectors are seeking natural molecules to develop various types of phytopharmaceutical products. Flavonoids have been reported in antioxidant and many medical/pharmacological activities. Monochoria angustifolia or Siam violet pearl medicinal plant is the newest species of the genus Monochoria C. Presl, which have long been consumed as food and herbal medicines. Though previous work showed that apigenin-7-O-glucoside is the most abundant antioxidant phytochemical found in this medicinal plant, the report on anti-aging activity is still lacking and needs to be filled in. The objective of this work is to explore anti-aging capacities of the most abundant antioxidant phytochemical reported in this plant using both in silico and in vitro assessments. In addition, pharmacokinetic properties were predicted. Interestingly, the results from both in silico and in vitro analysis showed a similar trend that apigenin-7-O-glucoside is a potential anti-aging agent against three enzymes. The pharmacokinetic properties, such as adsorption, distribution, metabolism, excretion and toxicity (ADMET), of this compound are also provided in this work. The current study is also the first report on anti-aging properties of this Thai medicinal plant. However, the safety and efficacy of future developed products from this compound and clinical study should be determined in the future.

1,3-Thiazolidin-4-ones are versatile heterocyclic scaffolds with diverse biological activities, however efficient synthesis and identification of potent lipid-lowering derivatives remain challenging. Here, we report a rapid, scalable sealed-tube, acid-catalyzed three-component synthesis of 2,3-diaryl-1,3-thiazolidin-4-ones, enabling broad substrate tolerance and the preparation of thirty synthetic derivatives, including twelve novel compounds, with moderate to excellent yields (from 25% to quantitative yield). Biological evaluation in HepG2 cells identified compound 4y as a non-toxic lead with superior lipid-lowering activity in both prophylactic and therapeutic oleic acid-induced steatosis models, comparable to the clinically used hepatoprotective agent silymarin. Mechanistic studies revealed that 4y robustly activates AMPKα, promoting lipid catabolism while suppressing lipogenesis, as confirmed by western blot, immunofluorescence, and molecular docking. Lipidomic profiling further demonstrated that 4y selectively reduces pathogenic ceramide and phosphatidylethanolamine species, highlighting its broad lipidome remodeling potential. These results establish 4y as a promising lead for the treatment of fatty liver disease and provide a practical synthetic platform for the development of thiazolidin-4-one-based metabolic therapeutics.